(Foundational)
(Expanded)
(Comprehensive)
BiomeBurden™ testing requires just two tubes—one whole blood and one serum—to yield clinically meaningful insights. This minimal draw enables a comprehensive view of the patient’s immune reactivity across microbial, fungal, and human tissue antigens.
Elevated antibodies to components of the microbiome, mycobiome, neutrophil activation markers, or self-antigens may reflect early immune dysregulation—often years before clinical symptoms emerge. These immune markers can provide critical clues in cases of unresolved inflammation, persistent GI symptoms, or suspected autoimmunity.
By identifying immune reactivity patterns early, providers can take a proactive approach—modulating immune balance, targeting microbial or environmental triggers, and supporting long-term resilience before overt disease manifests.